Angélique Da Silva
- Oncology top 10%
- Pulmonary and Respiratory Medicine
- Cardiology and Cardiovascular Medicine
- Immunology
- Molecular Biology
- Co-authors
- Joachim AlexandreCharles DolladilleMarion SassierAnne‐Flore PlaneDamien LegalloisBasile ChrétienSophie FédrizziVéronique Lelong‐Boulouard
- Topics
- Advanced Breast Cancer Therapies (6 papers)Chronic Lymphocytic Leukemia Research (6 papers)Cancer Treatment and Pharmacology (4 papers)
- Partner nations
- FranceLuxembourgNetherlands
In The Last Decade
Angélique Da Silva
17 papers receiving 576 citations
Hit Papers
Peers
Comparison fields: 5 of 54
- Oncology 451
- Pulmonary and Respiratory Medicine 176
- Cardiology and Cardiovascular Medicine 98
- Immunology 86
- Molecular Biology 51
Countries citing papers authored by Angélique Da Silva
This map shows the geographic impact of Angélique Da Silva's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Angélique Da Silva with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Angélique Da Silva more than expected).
Fields of papers citing papers by Angélique Da Silva
This network shows the impact of papers produced by Angélique Da Silva. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Angélique Da Silva. The network helps show where Angélique Da Silva may publish in the future.
Co-authorship network of co-authors of Angélique Da Silva
This figure shows the co-authorship network connecting the top 25 collaborators of Angélique Da Silva. A scholar is included among the top collaborators of Angélique Da Silva based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Angélique Da Silva. Angélique Da Silva is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 0 | |
| 2 | 1 | |
| 3 | 2 | |
| 4 | 0 | |
| 5 | 2 | |
| 6 | 1 | |
| 7 | 5 | |
| 8 | 10 | |
| 9 | 1 | |
| 10 | 10 | |
| 11 | 5 | |
| 12 | 6 | |
| 13 | 12 | |
| 14 | 13 | |
| 15 | 127 | |
| 16 | 4 | |
| 17 | 1 | |
| 18 | 3 | |
| 19 | Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancerbreakdown → | 377 |
About Angélique Da Silva
Angélique Da Silva is a scholar working on Toxicology, Genetics and Oncology, having authored 19 papers that have together received 580 indexed citations. Recurring topics across this work include Advanced Breast Cancer Therapies (6 papers), Chronic Lymphocytic Leukemia Research (6 papers) and Cancer Treatment and Pharmacology (4 papers). The work is most often cited by research in Oncology (451 citations), Pulmonary and Respiratory Medicine (176 citations) and Cardiology and Cardiovascular Medicine (98 citations). Angélique Da Silva has collaborated with scholars based in France, Luxembourg and Netherlands. Frequent co-authors include Joachim Alexandre, Charles Dolladille, Marion Sassier, Anne‐Flore Plane, Damien Legallois, Basile Chrétien, Sophie Fédrizzi, Véronique Lelong‐Boulouard, Stéphane Éderhy and Franck Thuny. Their work appears in journals such as European Heart Journal, Frontiers in Pharmacology and BMJ Open.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.